Human N-myristoyltransferase 1 (hNMT-1) catalyzes the covalent attachment of myristic acid to N-terminal glycine residues (myristoylation) of numerous protein substrates. Overexpression of hNMT-1 in colorectal and gallbladder cancers makes it a potential biomarker and drug design target for such cancers. In this study, we investigated hNMT-1 expression during the progression of eight different human cancers using quantitative RT-PCR. The study results showed that hNMT-1 was up-regulated in breast, colon, lung and ovarian cancers but not kidney, liver, prostate and thyroid cancers. This suggests a role for hNMT-1 as a biomarker for detection of breast, colon, lung and ovarian cancers. This study also suggests the available hNMT-1 inhibitors may be potential therapeutic agents against breast and lung cancers through all disease stages, although their use would likely be limited to early stage colon and ovarian cancers.
CITATION STYLE
Chen, L., Ling, B., Alcorn, J., & Yang, J. (2009). Quantitative Analysis of the Expression of Human N-myristoyltransferase 1 (hNMT-1) in Cancers. The Open Biomarkers Journal, 2(1), 6–10. https://doi.org/10.2174/1875318300902010006
Mendeley helps you to discover research relevant for your work.